S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NYSE:AGN

Allergan (AGN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$191.64
▼
$193.38
50-Day Range
$184.04
▼
$193.89
52-Week Range
$114.27
▼
$202.21
Volume
12.44 million shs
Average Volume
4.01 million shs
Market Capitalization
$63.50 billion
P/E Ratio
N/A
Dividend Yield
1.53%
Price Target
N/A
ProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

AGN stock logo

About Allergan (NYSE:AGN) Stock

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.


AGN Stock News Headlines

September 15, 2023 | thestreet.com
Allergan (AGN), Pfizer in Advanced Takeover Talks, Stocks Fall, Jim Cramer Weighs In
August 2, 2023 | ca.investing.com
Bausch + Lomb's Saunders doesn't expect more big deals in the near term
September 29, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
August 2, 2023 | za.investing.com
Bausch + Lomb posts better than expected Q2 earnings
August 1, 2023 | finance.yahoo.com
Allergan Aesthetics Announces First Ever JUVÉDERM® Day
July 24, 2023 | thestreet.com
Why Valeant Pharmaceuticals (VRX) Stock Is Up
July 7, 2023 | thestreet.com
Cramer -- Why a Pfizer Merger With Allergan Makes Sense
June 9, 2023 | msn.com
N.C. to receive $521M in opioid settlements with Teva, Allergan, CVS and Walgreens
September 29, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
June 9, 2023 | msn.com
Virginia receives $365.6 million in opioid settlements with Teva, Allergan, CVS, and Walgreens
May 22, 2023 | thestreet.com
Pfizer (PFE) Stock Sinks, Negotiating Break-Up Fee in Allergan Deal, Jim Cramer's View
May 17, 2023 | marketwatch.com
Bipolar Disorder Therapeutics Market Size, Growth Opportunities, Future Trends and Share with Revenue Forecast 2028
March 7, 2023 | thestreet.com
Biogen (BIIB) Stock Declines in After-Hours, Allergan Unlikely to Pursue Takeover
October 19, 2022 | finance.yahoo.com
Allergan Aesthetics and Girls Inc. Partner to Bridge the Gender Gap in STEM - Yahoo Finance
October 15, 2022 | thetimes.co.uk
Women sue over Allergan breast implants | Ireland | The Sunday Times - The Times
October 12, 2022 | finance.yahoo.com
Allergan Aesthetics Pledges Diamond Level Sponsorship for 2022 Breast Reconstruction Awareness Day - Yahoo Finance
October 11, 2022 | news.yahoo.com
New Paris bakery specializes in allergen-free foods - Yahoo News
October 11, 2022 | benzinga.com
Outlook on the Male Hypogonadism Global Market to 2030 - Featuring Allergan, Pfizer, Bayer and Endo Inter - Benzinga
October 11, 2022 | globenewswire.com
Ocular Implant Market Report (2022 to 2030) - Johnson and Johnson Services Inc., Carl Zeiss AG, Glaukos Corporation, Morcher GmbH, Allergan Inc. and Hoya Corporation - GlobeNewswire
October 9, 2022 | bizjournals.com
In Her Own Words: Nicci Levy's ALCHEMY 43 focuses on faces - Bizwomen - The Business Journals
October 7, 2022 | finance.yahoo.com
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio at the 2022 American Society for Dermatologic Surgery Meeting - Yahoo Finance
October 7, 2022 | prnewswire.com
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio at the 2022 American Society for Dermatologic Surgery Meeting - PR Newswire
October 7, 2022 | globenewswire.com
Global Acne Treatment Market (2022 Edition)– Analysis By Treatment, Treatment Modality, End-Users, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2023-2028) - GlobeNewswire
October 4, 2022 | finance.yahoo.com
The Global Botulinum Toxin Market size is expected to reach $10.5 billion by 2028, rising at a market growth of 10.8% CAGR during the forecast period - Yahoo Finance
October 4, 2022 | businesswire.com
Global Glaucoma Treatment Market Report 2022: Featuring Pfizer, F. Hoffmann-La Roche, Merck, Allergan & Others - ResearchAndMarkets.com - Business Wire
October 3, 2022 | nasdaq.com
Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales? - Nasdaq
October 3, 2022 | businesswire.com
Global Dry Eye Syndrome Therapeutics Market Report to 2029 - Featuring Abbott, AbbVie, Allergan and AstraZeneca Among Others - ResearchAndMarkets.com - Business Wire
See More Headlines
Receive AGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergan and its competitors with MarketBeat's FREE daily newsletter.

AGN Company Calendar

Last Earnings
2/10/2020
Today
9/29/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:AGN
Previous Symbol
NYSE:ACT
CUSIP
01849010
CIK
1578845
Web
www.allergan.com
Phone
862-261-7000
Fax
N/A
Employees
17,400
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$17.64
Trailing P/E Ratio
N/A
Forward P/E Ratio
11.56
P/E Growth
1.63
Net Income
$-5,271,000,000.00
Net Margins
-15.44%
Pretax Margin
N/A
Return on Equity
8.46%
Return on Assets
5.31%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
1.01
Quick Ratio
0.84

Sales & Book Value

Annual Sales
$16.09 billion
Price / Sales
3.95
Cash Flow
$36.70 per share
Price / Cash Flow
5.26
Book Value
$177.28 per share
Price / Book
1.09

Miscellaneous

Outstanding Shares
329,002,000
Free Float
N/A
Market Cap
$63.50 billion
Optionable
Optionable
Beta
1.20
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Brenton L. SaundersMr. Brenton L. Saunders (Age 49)
    Chairman, Pres & CEO
  • Mr. William Meury (Age 51)
    Exec. VP & Chief Commercial Officer
  • Dr. C. David Nicholson (Age 64)
    Exec. VP and Chief R&D Officer
  • Mr. Matthew M. WalshMr. Matthew M. Walsh (Age 52)
    Exec. VP & CFO
  • Mr. Wayne R. Swanton (Age 51)
    Exec. VP of Global Operations

Key Competitors

View All Competitors













AGN Stock - Frequently Asked Questions

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) released its quarterly earnings data on Monday, February, 10th. The company reported $5.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.57 by $0.65. The business earned $4.35 billion during the quarter, compared to analysts' expectations of $4.09 billion. Allergan had a negative net margin of 15.44% and a positive trailing twelve-month return on equity of 8.46%. The company's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the previous year, the company earned $4.29 EPS.

Is Allergan a good dividend stock?

Allergan (NYSE:AGN) pays an annual dividend of $2.96 per share and currently has a dividend yield of 1.53%. The dividend payout ratio is 16.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AGN will have a dividend payout ratio of 16.33% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AGN.

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $193.02.

How much money does Allergan make?

Allergan (NYSE:AGN) has a market capitalization of $63.50 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis.

How many employees does Allergan have?

The company employs 17,400 workers across the globe.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The official website for the company is www.allergan.com. The company can be reached via phone at 862-261-7000 or via email at investorrelations@allergan.com.

This page (NYSE:AGN) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -